

DT12 Rec'd PCT/PTO 16 MAR 2005

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for release through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 2

Complete If Known

Application Number	Unassigned
Filing Date	March 16, 2005
First Named Inventor	Thorsten HEINZEL et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	LEDER-15

10/528104

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
JA	1	WO	9735990		Jamison Timothy F	October 2, 1997		
I	2	EP	1050581		Medical & Biolog Lab Co LTD	November 8, 2000		
I	3	WO	0071703		Methylgene INC.	November 30, 2000		

Examiner
SignatureDate
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

10/528104

DT ec'd PCT/PTO 16 MAR 2005

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	Unassigned
		Filing Date	March 16, 2005
		First Named Inventor	Thorsten HEINZEL et al.
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
Sheet	2	of	2
		Attorney Docket Number	LEDER-15

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	4	SU G H et al: "A NOVEL HISTONE DEACETYLASE INHIBITOR IDENTIFIED BY HIGH-THROUGHPUTTRANSCRIPTIONAL SCREENING OF A COMPOUND LIBRARY" CANCER RESEARCH, AMERICAN ASSOCIATION FO RCANCER REASEARCH, BALTIMORE, MD, US vol. 60, no. 12, 15 June 2000 pages 3137-3142, XP000985980	
	5	KWON H J et al: "A HISTONE DEACETYLASE INHIBITOR, TRICHOSTATIN A , INDUCES APOPTOSIS THROUGH SUPPRESSION OF ANTI-APOPTOTIC FACTORS, C-IAP-1 AND C-IAP-2 IN HUMAN PROTSTATE EPITHELIAL CELLS" PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, NEW YORK, NY, US vol. 40, March 1999, pages 581 XP002180771	
	6	SCHMIDT K ET AL: "INHIBITORS OF HISTONE DEACETYLASE SUPPRESS THE GROWTH OF MCF-7 BREAST CANCER CELLS" ARCHIV DER PHARMAZIE, VCH VERLAGSGESELLSCHAFT MBH, WEINHEIM, DE vol. 332, no. 10, 1999, pages 353-357, XP000985303	
	7	WARELL R P ET AL: "THERAPEUTIC TARGETING OF TRANSCRIPTION IN ACUTE PROMYELOCYTIC LEUKEMIA BY USE OF AN INHIBITOR OF HISTON DEACETYLASE" JOURNAL OF THE NATIONAL CANCER INSTITUTE, US DEPT, OF HEALTH, EDUCATION AND WELFARE, PUBLIC HEALTH, US, vol. 90, no. 21, November 1998 pages 1621-1625; XP002928827	
	8	JUNG M: "INHIBITORS OF HISTONE DEACETYLASE AS NEW ANTICANCER AGENTS" CURRENT MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBLISHERS BV, BE vol. 8, 2001, pages 1505-1511, XP001098704	
	9	GREENBERG V L ET AL: "HISTONE DEACETYLASE INHIBITORS PROMOTE APOPTOSIS AND DIFFERENTIAL CELL CYCLE ARREST IN ANAPLASTIC THYROID CANCER CELLS" THYROID, MARY ANN LIEBERT, NEW YORK, NY, US, vol. 11, no. 4 April 2001 pages 315-325, XP009003316	
	10	"SMALL MOLECULE INHIBITORS OF HISTONE DEACETYLASE" EXPERT OPINION ON THERAPEUTIC PATENTS, ASHLEY PUBLICATIONS, GB, vol. 12, no. 6, 2002, pages 943-947, XP001120539	

Examiner Signature		Date Considered	5-5-07
-----------------------	--	--------------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.